Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Insmed

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 912

Market Cap: $13.2B

Website

Introduction: Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Clinical Trials

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Conditions: Pulmonary Arterial Hypertension
Pulmonary Hypertension, Interstitial Lung Disease

First Posted Date: 2025-04-23

Last Posted Date: 2025-06-27

Lead Sponsor: Insmed Incorporated

Registration Number: NCT06939647

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Brensocatib
Drug: Placebo

First Posted Date: 2024-11-13

Last Posted Date: 2025-06-29

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 204

Registration Number: NCT06685835

Locations: 🇺🇸
USA007, Sacramento, California, United States
🇺🇸
USA026, Coral Gables, Florida, United States
🇺🇸
USA021, Margate, Florida, United States

and more 59 locations

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Brensocatib Oral Solution
Drug: Brensocatib Oral Tablet

First Posted Date: 2024-04-03

Last Posted Date: 2024-06-13

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 24

Registration Number: NCT06344728

Locations: 🇺🇸
USA001, Dallas, Texas, United States

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: SLIT™ Amikacin
Drug: Placebo

First Posted Date: 2024-02-02

Last Posted Date: 2024-02-02

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 18

Registration Number: NCT06238856

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: C16TR
Drug: Placebo
Drug: Tyvaso®

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 24

Registration Number: NCT06193031

Locations: 🇺🇸
USA001, Los Angeles, California, United States

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brensocatib

First Posted Date: 2023-12-21

Last Posted Date: 2024-01-22

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 20

Registration Number: NCT06178783

Locations: 🇺🇸
USA001, Dallas, Texas, United States

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treprostinil Palmitil Inhalation Powder
Drug: Placebo

First Posted Date: 2023-10-19

Last Posted Date: 2023-10-19

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 42

Registration Number: NCT06091579

Locations: 🇺🇸
USA001, Austin, Texas, United States

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 2

Active, not recruiting

Conditions: Chronic Rhinosinusitis Without Nasal Polyps

Interventions: Drug: Placebo
Drug: Brensocatib
Drug: Mometasone furoate nasal spray (MFNS)

First Posted Date: 2023-08-28

Last Posted Date: 2025-05-11

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 288

Registration Number: NCT06013241

Locations: 🇺🇸
USA034, Tucson, Arizona, United States
🇺🇸
USA002, Roseville, California, United States
🇺🇸
USA006, Upland, California, United States

and more 97 locations

A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Liposomal Amikacin for Inhalation

First Posted Date: 2023-08-21

Last Posted Date: 2023-08-21

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 6

Registration Number: NCT05999942

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brensocatib
Drug: Clarithromycin

First Posted Date: 2023-07-28

Last Posted Date: 2023-12-11

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 22

Registration Number: NCT05965570

Locations: 🇺🇸
USA001, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy